Kyverna Therapeutics (KYTX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $5.67, -5.03% vs the prior close of $5.97.
- Volume 724.52K shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
KYTX slides 5.0% to $5.67, a 52-week low. Closed at $5.67, -5.03% vs the prior close of $5.97. Day range $5.64–$6.01, opened at $6.01.
KYTX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — KYTX slides 5.0% to $5.67, a 52-week low
- Closed at $5.67, -5.03% vs the prior close of $5.97. Day range $5.64–$6.01, opened at $6.01.
- Volume was 724.52K shares, 0.9x its 50-day average of 849.04K.
- Price is -23.5% vs its 50-day average ($7.42) and -31.1% vs its 200-day average ($8.23).
- 52-week range $5.61–$13.67; today's close sits at 1% of that range, 58.5% below the 52-week high.
Oct 15, 2026 — KYTX jumps 5.0% to $5.97
- Closed at $5.97, +5.01% vs the prior close of $5.68. Day range $5.67–$6.02, opened at $5.67.
- Volume was 779.40K shares, 0.9x its 50-day average of 844.99K.
- Price is -19.9% vs its 50-day average ($7.46) and -27.6% vs its 200-day average ($8.25).
- 52-week range $5.61–$13.67; today's close sits at 4% of that range, 56.3% below the 52-week high.
Oct 14, 2026 — KYTX dips 1.5% to $5.68, a 52-week low, 3 down days in a row
- Closed at $5.68, -1.47% vs the prior close of $5.77. Day range $5.61–$5.84, opened at $5.76.
- Volume was 1.28M shares, 1.5x its 50-day average of 830.76K.
- Price is -24.1% vs its 50-day average ($7.49) and -31.2% vs its 200-day average ($8.27).
- 52-week range $5.61–$13.67; today's close sits at 1% of that range, 58.4% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — KYTX slides 7.1% to $5.77, a 52-week low
- Closed at $5.77, -7.09% vs the prior close of $6.21. Day range $5.76–$6.17, opened at $6.17.
- Volume was 1.24M shares, 1.5x its 50-day average of 822.38K.
- Price is -23.4% vs its 50-day average ($7.53) and -30.4% vs its 200-day average ($8.29).
- 52-week range $5.76–$13.67; today's close sits at 0% of that range, 57.8% below the 52-week high.
Oct 12, 2026 — KYTX dips 2.8% to $6.21
- Closed at $6.21, -2.82% vs the prior close of $6.39. Day range $6.19–$6.46, opened at $6.34.
- Volume was 417.10K shares, 0.5x its 50-day average of 824.58K — lighter than usual.
- Price is -17.9% vs its 50-day average ($7.57) and -25.2% vs its 200-day average ($8.30).
- 52-week range $5.96–$13.67; today's close sits at 3% of that range, 54.6% below the 52-week high.
Oct 9, 2026 — KYTX jumps 3.4% to $6.39, 3 up days in a row
- Closed at $6.39, +3.40% vs the prior close of $6.18. Day range $6.18–$6.58, opened at $6.20.
- Volume was 876.40K shares, 1.1x its 50-day average of 819.92K.
- Price is -15.8% vs its 50-day average ($7.59) and -23.2% vs its 200-day average ($8.32).
- 52-week range $5.96–$13.67; today's close sits at 6% of that range, 53.3% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — KYTX ends flat (+0.2%) to $6.18
- Closed at $6.18, +0.16% vs the prior close of $6.17. Day range $5.96–$6.22, opened at $6.06.
- Volume was 1.32M shares, 1.6x its 50-day average of 814.79K.
- Price is -18.8% vs its 50-day average ($7.61) and -25.8% vs its 200-day average ($8.32).
- 52-week range $5.93–$13.67; today's close sits at 3% of that range, 54.8% below the 52-week high.
Oct 7, 2026 — KYTX ends flat (+0.2%) to $6.17
- Closed at $6.17, +0.16% vs the prior close of $6.16. Day range $6.02–$6.31, opened at $6.12.
- Volume was 650.30K shares, 0.8x its 50-day average of 823.13K.
- Price is -19.1% vs its 50-day average ($7.63) and -25.9% vs its 200-day average ($8.33).
- 52-week range $5.30–$13.67; today's close sits at 10% of that range, 54.9% below the 52-week high.
Oct 6, 2026 — KYTX dips 2.5% to $6.16, a 6-month low
- Closed at $6.16, -2.53% vs the prior close of $6.32. Day range $6.13–$6.45, opened at $6.38.
- Volume was 739.40K shares, 0.9x its 50-day average of 832.23K.
- Price is -19.5% vs its 50-day average ($7.65) and -26.1% vs its 200-day average ($8.33).
- 52-week range $5.30–$13.67; today's close sits at 10% of that range, 54.9% below the 52-week high.
Oct 5, 2026 — KYTX rises 1.6% to $6.32
- Closed at $6.32, +1.61% vs the prior close of $6.22. Day range $6.00–$6.43, opened at $6.30.
- Volume was 813.50K shares, 1.0x its 50-day average of 832.98K.
- Price is -17.8% vs its 50-day average ($7.69) and -24.2% vs its 200-day average ($8.34).
- 52-week range $5.30–$13.67; today's close sits at 12% of that range, 53.8% below the 52-week high.
Oct 2, 2026 — KYTX slides 4.6% to $6.22, a 6-month low, 3 down days in a row
- Closed at $6.22, -4.60% vs the prior close of $6.52. Day range $6.17–$6.75, opened at $6.62.
- Volume was 1.18M shares, 1.4x its 50-day average of 822.33K.
- Price is -19.3% vs its 50-day average ($7.71) and -25.6% vs its 200-day average ($8.36).
- 52-week range $5.30–$13.67; today's close sits at 11% of that range, 54.5% below the 52-week high.
- That makes 3 straight losses.
KYTX latest news & SEC filings
Every SEC filing by or about KYTX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$38.32M (prior year -$42.08M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.63 (prior year -$0.97) (loss narrowed vs Jun 30, 2025)
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 29, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 27, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jul 9, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Things to know before you trade KYTX
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 12, 2026, Mar 26, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.71% (largest 7.1%).
- Liquidity: about 1.03M shares (≈$5.87M) trade per day on average.
- 52-week position: $5.67 vs a range of $5.61–$13.67 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 20 open-market buys, 4 sales; latest: Beth C Seidenberg bought 133,333 shares on Dec 18, 2025.
- Latest filings: 8-K Sep 24, 2026; 10-Q Aug 11, 2026; 8-K Aug 11, 2026.
- Share count: 61.84M shares outstanding (Aug 3, 2026), +43.0% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
KYTX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 6.01 | 6.01 | 5.64 | 5.67 | 724.52K |
| Oct 15, 2026 | 5.67 | 6.02 | 5.67 | 5.97 | 779.40K |
| Oct 14, 2026 | 5.76 | 5.84 | 5.61 | 5.68 | 1.28M |
| Oct 13, 2026 | 6.17 | 6.17 | 5.76 | 5.77 | 1.24M |
| Oct 12, 2026 | 6.34 | 6.46 | 6.19 | 6.21 | 417.10K |
| Oct 9, 2026 | 6.20 | 6.58 | 6.18 | 6.39 | 876.40K |
| Oct 8, 2026 | 6.06 | 6.22 | 5.96 | 6.18 | 1.32M |
| Oct 7, 2026 | 6.12 | 6.31 | 6.02 | 6.17 | 650.30K |
| Oct 6, 2026 | 6.38 | 6.45 | 6.13 | 6.16 | 739.40K |
| Oct 5, 2026 | 6.30 | 6.43 | 6.00 | 6.32 | 813.50K |
| Oct 2, 2026 | 6.62 | 6.75 | 6.17 | 6.22 | 1.18M |
| Oct 1, 2026 | 6.80 | 6.91 | 6.51 | 6.52 | 787.50K |
| Sep 30, 2026 | 6.88 | 7.10 | 6.73 | 6.80 | 746.20K |
| Sep 29, 2026 | 6.83 | 6.95 | 6.75 | 6.84 | 826.30K |
| Sep 28, 2026 | 6.72 | 6.95 | 6.65 | 6.82 | 997.00K |
| Sep 25, 2026 | 6.99 | 7.01 | 6.62 | 6.81 | 1.50M |
| Sep 24, 2026 | 7.80 | 7.92 | 6.68 | 6.99 | 3.28M |
| Sep 23, 2026 | 7.50 | 7.54 | 6.99 | 7.07 | 1.03M |
| Sep 22, 2026 | 7.18 | 7.59 | 7.11 | 7.51 | 836.50K |
| Sep 21, 2026 | 7.25 | 7.26 | 6.99 | 7.12 | 678.50K |
About Kyverna Therapeutics
Kyverna Therapeutics (KYTX) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in EMERYVILLE, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1994702.
KYTX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Mert Aktar | Director | May 29, 2026 |
| Warner Weston Biddle | Chief Executive Officer | Mar 17, 2026 |
| Ian T Clark | Director | May 29, 2026 |
| Fred E Cohen | Director | May 29, 2026 |
| Sravan Kumar Emany | Director | Feb 26, 2026 |
| Andrew Craig Miller | Director | Mar 4, 2026 |
| Beth C Seidenberg | Director | May 29, 2026 |
| Christi Shaw | Executive Chairperson | May 29, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Warner Weston Biddle | Chief Executive Officer | Mar 17, 2026 |
| Nadia Dac | Chief Commercial Officer | May 6, 2026 |
| Naji Gehchan | See Remarks | Mar 17, 2026 |
| Marc Grasso | Chief Financial Officer | Mar 17, 2026 |
| Gregory S. Martini | Chief Financial Officer | May 20, 2026 |
| Mayobanex Pujols | Chief Technology Officer | Feb 11, 2026 |
| Christi Shaw | Executive Chairperson | May 29, 2026 |
| Karen Marie Walker | Chief Technology Officer | Dec 17, 2025 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Dec 18, 2025 | Beth C Seidenberg | Buy | 133,333 | $7.50 |
| Dec 18, 2025 | Beth C Seidenberg | Buy | 133,333 | $7.50 |
| Dec 18, 2025 | Beth C Seidenberg | Buy | 133,333 | $7.50 |
| Dec 18, 2025 | Beth C Seidenberg | Buy | 133,333 | $7.50 |
| Dec 18, 2025 | Biopartners Opportunity Fund I, L.P. Westlake | Buy | 133,333 | $7.50 |
| Dec 18, 2025 | Biopartners Opportunity Fund I, L.P. Westlake | Buy | 133,333 | $7.50 |
| Dec 18, 2025 | Biopartners Opportunity Gp I, Llc Westlake | Buy | 133,333 | $7.50 |
| Dec 18, 2025 | Biopartners Opportunity Gp I, Llc Westlake | Buy | 133,333 | $7.50 |
| Dec 18, 2025 | Biopartners Gp I, Llc Westlake | Buy | 133,333 | $7.50 |
| Dec 18, 2025 | Biopartners Gp I, Llc Westlake | Buy | 133,333 | $7.50 |
| Dec 18, 2025 | Biopartners Fund I, L.P. Westlake | Buy | 133,333 | $7.50 |
| Dec 18, 2025 | Biopartners Fund I, L.P. Westlake | Buy | 133,333 | $7.50 |
| Dec 18, 2025 | Biopartners Opportunity Fund I, L.P. Westlake | Buy | 133,333 | $7.50 |
| Dec 18, 2025 | Biopartners Opportunity Fund I, L.P. Westlake | Buy | 133,333 | $7.50 |
| Dec 18, 2025 | Biopartners Opportunity Gp I, Llc Westlake | Buy | 133,333 | $7.50 |
KYTX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-161.31M | -3.64 | $-153.71M |
| Dec 31, 2024 | — | $-127.48M | -3.33 | $-114.25M |
| Dec 31, 2023 | — | $-60.37M | -89.61 | $-52.41M |
Latest balance sheet: total assets $219.82M, total liabilities $54.27M, cash $31.81M (as of Jun 30, 2026).
KYTX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $8.02 |
| May 12, 2026 | 8-K Item 2.02 (results) | $10.23 |
| Mar 26, 2026 | 8-K Item 2.02 (results) | $8.03 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $8.23 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $7.33 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $3.02 |
| May 13, 2025 | 8-K Item 2.02 (results) | $2.32 |
| Mar 27, 2025 | 8-K Item 2.02 (results) | $2.36 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $5.06 |
| Aug 12, 2024 | 8-K Item 2.02 (results) | — |
| May 14, 2024 | 8-K Item 2.02 (results) | — |
| Mar 26, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on KYTX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.